Immune Medicine

B-

Spinoff of Adaptive Biotechnologies (ADPT) · Biotechnology · Expected YE 2026 path

Separates profitable MRD diagnostics (clonoSEQ) from the earlier-stage Immune Medicine drug-discovery platform

Snapshot Across Reports

Oct 30, 2026Sep 30, 2026Aug 31, 2026Jul 31, 2026Jun 30, 2026
StatusUpcomingUpcomingUpcomingUpcomingUpcoming
Investment GradeB-B-B-B-B-
RevenueNot disclosedNot disclosedNot disclosedNot disclosedNot disclosed
Expected DateYE 2026 pathYE 2026 pathYE 2026 pathPath by YE 2026Path by YE 2026

⚠ Auto-generated profile — not editorially reviewed.

This summary is compiled automatically from our tracked report data. A reviewed in-depth analysis is planned. For further detail ▸ read the Oct 30, 2026 report.